Piperacillin Acid (CAS 61477-96-1) Market By Purity (99%, 97%, 95%, and Others); By Application (Therapeutic (Respiratory Tract Infections, Skin And Skin Structure Infections, Urinary Tract Infections, Intra-Abdominal Infections, Community-acquired Pneumonia, and Others), Clinical In-Vitro Microbiological Antimicrobial Susceptibility Tests (Panels, Discs, and MIC Strips), Plant Biology, and Others); By End Users (Research Institutions, Pharmaceutical & Drug Manufacturing Companies, Others); By Distribution Channels (Online and Offline); By Region (U.S., Canada, Mexico, Rest of North America, France, The UK, Spain, Germany, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia), Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America); – Regional Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 - 2029
Industry Trends
Piperacillin acid (CAS 61477-96-1) is a broad spectrum antibiotic which belongs to the drug class called as ureidopenicillin. The product is increasingly used for numerous applications such as the treatment of respiratory tract infections, urinary tract infections, community-acquired pneumonia, amongst others. Piperacillin acid can reduce the susceptibility to cleavage, which is caused by penetration into gram-negative bacteria by beta lactamase enzymes that are meant to counter them. Hence, in the times of the Covid-19 pandemic, the piperacillin acid (CAS 61477-96-1) market indicates promising growth prospects. Changes in lifestyle and exposure to pollutions has resulted in the weakening of immune systems, especially in the urban areas. Community acquired pneumonia is a serious cause of concern in developing and under developed countries. India was responsible for around 23% of the total cases of Community-acquired pneumonia (CAP), and the case fatality rates were between 14% and 30%. Demand from emerging markets such as China and India, which comprises of higher density of population, is another factor aiding the market growth.
Increasing investment towards research & development (R&D) activities is driving the growth of global piperacillin acid (CAS 61477-96-1) market. Due to the discovery of new viruses, there is a necessity for preparations that require constant research and development of medicines and vaccines. However, the plethora of counter-reactions associated with the administration of the drug is impeding its penetration in the global piperacillin acid (CAS 61477-96-1) market.
Purity Outlook:
In terms of purity, the global piperacillin acid (CAS 61477-96-1) market is classified into 99% purity, 97% purity, 95% purity, and others. In 2020, the 99% purity segment held the largest market share. 99% pure piperacillin acid is the third generation semi synthetic penicillin, which has wide spectrum and low toxicity. Its bactericidal effect is better than that of the present semi synthetic penicillin.
Application Outlook:
The application segment in the global piperacillin acid (CAS 61477-96-1) market has been broadly segmented into therapeutic applications, clinical in-vitro microbiological antimicrobial susceptibility tests (Panels, Discs, and MIC Strips), plant biology, and others. The therapeutic applications segment has been further classified into respiratory tract infections, skin and skin structure infections, urinary tract infections, intra-abdominal infections, community-acquired pneumonia, and others.
In 2020, therapeutic applications segment held the largest share in the global piperacillin acid (CAS 61477-96-1) market. Respiratory tract infections, under the therapeutic segment, occupied the largest market share in 2020, owing to the faulty lifestyle in the modern world, which has caused different kinds of breathing problems among people at large.
End User Outlook:
End users segment in the global piperacillin acid (CAS 61477-96-1) market has been categorised into research institutions and pharmaceutical & drug manufacturing companies amongst others. In 2020, pharmaceutical & drug manufacturing companies segment accounted for the largest market share due to a rise in the drug approvals by the regulatory bodies. Rapid approvals is fuelling the pharmaceutical manufacturing procedures exponentially. For example, in 2018, the Food & Drug Administration of America (FDA) approved 59 drugs, followed by 49 drugs in 2019. Till April 2020, the FDA had approved 15 drugs.
Distribution Channel Outlook:
On the basis of distribution channels, the global piperacillin acid (CAS 61477-96-1) market is bifurcated into online distribution channels and offline distribution channels. In 2020, offline distribution channels segment held the larger market. However, during the forecast period, online distribution channels segment is estimated to rapidly extend its market share. The increasing investments by manufacturers towards diversification of distribution channels along with growing need to expand consumer reach is anticipated to supplement the segment’s growth over the future years.
Region Outlook:
In 2020, North America region dominated the global piperacillin acid (CAS 61477-96-1) market owing to availability of advanced medical facilities. During the forecast period, Asia Pacific region is estimated to witness highest CAGR due to increasing investment in medical sector and support from the governments of various countries such as India, Japan, Singapore, and South Korea in the region.
The global piperacillin acid (CAS 61477-96-1) market accounted for US$ 250.75 Mn in 2020, and is expected to grow at a CAGR of 4.9% during the forecast years (2021-2029).
Global Piperacillin Acid (CAS 61477-96-1) Market Revenue & Forecast, (US$ Million), 2015 – 2029
Competitive Landscape
The report provides both, qualitative and quantitative research of piperacillin acid (CAS 61477-96-1) market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global piperacillin acid (CAS 61477-96-1) market are AK Scientific Inc., ALB Technology Limited., BOC Sciences, Glentham Life Sciences Limited, GoldBio, hairuichem.com, Jiangxi Fushine Pharmaceutical Co. Ltd., Jigs chemical, LGC Limited, LKT Laboratories, mos-chemical.com (MOSINTER GROUP LIMITED), MuseChem, Targetmol, Thermo Fisher Scientific (Alfa Aesar), TOKU-E, and United States Biological amongst others.
Global Piperacillin Acid (CAS 61477-96-1) Market:
By Purity
- 99%
- 97%
- 95%
- Others
By Application
- Therapeutic
- Respiratory Tract Infections
- Skin And Skin Structure Infections
- Urinary Tract Infections
- Intra-Abdominal Infections
- Community-acquired Pneumonia
- Others
- Clinical In-Vitro Microbiological Antimicrobial Susceptibility Tests (Panels, Discs, and MIC Strips)
- Plant Biology
- Others
By End Users
- Research Institutions
- Pharmaceutical & Drug Manufacturing Companies
- Others
By Distribution Channel
- Online
- Offline
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2018
1.2.2. Base
Year: 2019
1.2.3. Forecast
Years: 2020 – 2028
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Piperacillin Acid (CAS 61477-96-1)
Market
6. Market Synopsis:
Piperacillin Acid (CAS 61477-96-1) Market
7. Piperacillin Acid (CAS 61477-96-1) Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Piperacillin Acid (CAS 61477-96-1) Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Piperacillin Acid (CAS 61477-96-1) Market
7.6. Porter’s
Five Force Analysis
7.7. Value
Chain Analysis
7.8. Impact of Covid-19 on Piperacillin Acid (CAS 61477-96-1) Market
8. Global Piperacillin Acid (CAS 61477-96-1) Market Analysis and
Forecasts, 2020 – 2028
8.1. Overview
8.1.1. Global
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
8.2. Global
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts, By
Purity
8.2.1. 99%
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 – 2019
8.2.1.3. Market Forecast, 2020 – 2028
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 – 2019
8.2.1.5.1.2. Market
Forecast, 2020 – 2028
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2019
8.2.1.5.2.2. Market
Forecast, 2020 – 2028
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2019
8.2.1.5.3.2. Market
Forecast, 2020 – 2028
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2019
8.2.1.5.4.2. Market
Forecast, 2020 – 2028
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 – 2019
8.2.1.5.5.2. Market
Forecast, 2020 – 2028
8.2.2. 97%
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 – 2019
8.2.2.3. Market Forecast, 2020 – 2028
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 – 2019
8.2.2.5.1.2. Market
Forecast, 2020 – 2028
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2019
8.2.2.5.2.2. Market
Forecast, 2020 – 2028
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2019
8.2.2.5.3.2. Market
Forecast, 2020 – 2028
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2019
8.2.2.5.4.2. Market
Forecast, 2020 – 2028
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 – 2019
8.2.2.5.5.2. Market
Forecast, 2020 – 2028
8.2.3. 95%
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 – 2019
8.2.3.3. Market Forecast, 2020 – 2028
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 – 2019
8.2.3.5.1.2. Market
Forecast, 2020 – 2028
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2019
8.2.3.5.2.2. Market
Forecast, 2020 – 2028
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2019
8.2.3.5.3.2. Market
Forecast, 2020 – 2028
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2019
8.2.3.5.4.2. Market
Forecast, 2020 – 2028
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 – 2019
8.2.3.5.5.2. Market
Forecast, 2020 – 2028
8.2.4. Others
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 – 2019
8.2.4.3. Market Forecast, 2020 – 2028
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 – 2019
8.2.4.5.1.2. Market
Forecast, 2020 – 2028
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 – 2019
8.2.4.5.2.2. Market
Forecast, 2020 – 2028
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 – 2019
8.2.4.5.3.2. Market
Forecast, 2020 – 2028
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 – 2019
8.2.4.5.4.2. Market
Forecast, 2020 – 2028
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 – 2019
8.2.4.5.5.2. Market
Forecast, 2020 – 2028
8.3. Key
Segment for Channeling Investments
8.3.1. By
Purity
9. Global Piperacillin Acid (CAS 61477-96-1) Market Analysis and
Forecasts, 2020 – 2028
9.1. Overview
9.2. Global
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts, By
Application
9.2.1. Therapeutic
(Definition, Market Estimation and Penetration, 2015 – 2019, Market Estimation
(2015 – 2019), Market Forecast (2020 – 2028), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Respiratory Tract Infections,
Skin And Skin Structure Infections, Urinary Tract Infections, Intra-Abdominal
Infections, Community-acquired Pneumonia, Others)
9.2.1.1. Respiratory Tract Infections
9.2.1.2. Skin And Skin Structure Infections
9.2.1.3. Urinary Tract Infections
9.2.1.4. Intra-Abdominal Infections
9.2.1.5. Community-acquired Pneumonia
9.2.1.6. Others
9.2.2. Clinical
In-Vitro Microbiological Antimicrobial Susceptibility Tests (Panels, Discs, and
MIC Strips)
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 – 2019
9.2.2.3. Market Forecast, 2020 – 2028
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 – 2019
9.2.2.5.1.2. Market
Forecast, 2020 – 2028
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2019
9.2.2.5.2.2. Market
Forecast, 2020 – 2028
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2019
9.2.2.5.3.2. Market
Forecast, 2020 – 2028
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2019
9.2.2.5.4.2. Market
Forecast, 2020 – 2028
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 – 2019
9.2.2.5.5.2. Market
Forecast, 2020 – 2028
9.2.3. Plant
Biology
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 – 2019
9.2.3.3. Market Forecast, 2020 – 2028
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 – 2019
9.2.3.5.1.2. Market
Forecast, 2020 – 2028
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2019
9.2.3.5.2.2. Market
Forecast, 2020 – 2028
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2019
9.2.3.5.3.2. Market
Forecast, 2020 – 2028
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2019
9.2.3.5.4.2. Market
Forecast, 2020 – 2028
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 – 2019
9.2.3.5.5.2. Market
Forecast, 2020 – 2028
9.2.4. Others
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 – 2019
9.2.4.3. Market Forecast, 2020 – 2028
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 – 2019
9.2.4.5.1.2. Market
Forecast, 2020 – 2028
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 – 2019
9.2.4.5.2.2. Market
Forecast, 2020 – 2028
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 – 2019
9.2.4.5.3.2. Market
Forecast, 2020 – 2028
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 – 2019
9.2.4.5.4.2. Market
Forecast, 2020 – 2028
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 – 2019
9.2.4.5.5.2. Market
Forecast, 2020 – 2028
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global Piperacillin Acid (CAS 61477-96-1) Market Analysis and
Forecasts, 2020 – 2028
10.1. Overview
10.2. Global
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts, By
End Users
10.2.1. Research
Institutions
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 – 2019
10.2.1.3. Market Forecast, 2020 – 2028
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 – 2019
10.2.1.5.1.2. Market
Forecast, 2020 – 2028
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2019
10.2.1.5.2.2. Market
Forecast, 2020 – 2028
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2019
10.2.1.5.3.2. Market
Forecast, 2020 – 2028
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2019
10.2.1.5.4.2. Market
Forecast, 2020 – 2028
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 – 2019
10.2.1.5.5.2. Market
Forecast, 2020 – 2028
10.2.2. Pharmaceutical
and Drug Manufacturing Companies
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 – 2019
10.2.2.3. Market Forecast, 2020 – 2028
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 – 2019
10.2.2.5.1.2. Market
Forecast, 2020 – 2028
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2019
10.2.2.5.2.2. Market
Forecast, 2020 – 2028
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2019
10.2.2.5.3.2. Market
Forecast, 2020 – 2028
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2019
10.2.2.5.4.2. Market
Forecast, 2020 – 2028
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 – 2019
10.2.2.5.5.2. Market
Forecast, 2020 – 2028
10.2.3. Others
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 – 2019
10.2.3.3. Market Forecast, 2020 – 2028
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 – 2019
10.2.3.5.1.2. Market
Forecast, 2020 – 2028
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2019
10.2.3.5.2.2. Market
Forecast, 2020 – 2028
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2019
10.2.3.5.3.2. Market
Forecast, 2020 – 2028
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2019
10.2.3.5.4.2. Market
Forecast, 2020 – 2028
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 – 2019
10.2.3.5.5.2. Market
Forecast, 2020 – 2028
10.3. Key
Segment for Channeling Investments
10.3.1. By End
Users
11. Global Piperacillin Acid (CAS 61477-96-1) Market Analysis and
Forecasts, 2020 – 2028
11.1. Overview
11.2. Global
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
11.2.1. Online
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 – 2019
11.2.1.3. Market Forecast, 2020 – 2028
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 – 2019
11.2.1.5.1.2. Market
Forecast, 2020 – 2028
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2019
11.2.1.5.2.2. Market
Forecast, 2020 – 2028
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2019
11.2.1.5.3.2. Market
Forecast, 2020 – 2028
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2019
11.2.1.5.4.2. Market
Forecast, 2020 – 2028
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 – 2019
11.2.1.5.5.2. Market
Forecast, 2020 – 2028
11.2.2. Offline
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 – 2019
11.2.2.3. Market Forecast, 2020 – 2028
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 – 2019
11.2.2.5.1.2. Market
Forecast, 2020 – 2028
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2019
11.2.2.5.2.2. Market
Forecast, 2020 – 2028
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2019
11.2.2.5.3.2. Market
Forecast, 2020 – 2028
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2019
11.2.2.5.4.2. Market
Forecast, 2020 – 2028
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 – 2019
11.2.2.5.5.2. Market
Forecast, 2020 – 2028
11.3. Key
Segment for Channeling Investments
11.3.1. By
Distribution Channel
12. North America Piperacillin Acid (CAS 61477-96-1) Market
Analysis and Forecasts, 2020 - 2028
12.1. Overview
12.1.1. North
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
12.2. North
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Purity
12.2.1. 99%
12.2.2. 97%
12.2.3. 95%
12.2.4. Others
12.3. North
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Application
12.3.1. Therapeutic
12.3.1.1. Respiratory Tract Infections
12.3.1.2. Skin And Skin Structure Infections
12.3.1.3. Urinary Tract Infections
12.3.1.4. Intra-Abdominal Infections
12.3.1.5. Community-acquired Pneumonia
12.3.1.6. Others
12.3.2. Clinical
In-Vitro Microbiological Antimicrobial Susceptibility Tests (Panels, Discs, and
MIC Strips)
12.3.3. Plant
Biology
12.3.4. Others
12.4. North
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By End Users
12.4.1. Research
Institutions
12.4.2. Pharmaceutical
and Drug Manufacturing Companies
12.4.3. Others
12.5. North
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.5.1. Online
12.5.2. Offline
12.6. North
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
and Forecasts, By Purity
12.6.1.1.1. 99%
12.6.1.1.2. 97%
12.6.1.1.3. 95%
12.6.1.1.4. Others
12.6.1.2. U.S Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
and Forecasts, By Application
12.6.1.2.1. Therapeutic
12.6.1.2.1.1. Respiratory
Tract Infections
12.6.1.2.1.2. Skin
And Skin Structure Infections
12.6.1.2.1.3. Urinary
Tract Infections
12.6.1.2.1.4. Intra-Abdominal
Infections
12.6.1.2.1.5. Community-acquired
Pneumonia
12.6.1.2.1.6. Others
12.6.1.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
12.6.1.2.3. Plant Biology
12.6.1.2.4. Others
12.6.1.3. U.S Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
and Forecasts, By End Users
12.6.1.3.1. Research Institutions
12.6.1.3.2. Pharmaceutical and Drug Manufacturing Companies
12.6.1.3.3. Others
12.6.1.4. U.S Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
12.6.1.4.1. Online
12.6.1.4.2. Offline
12.6.2. Canada
12.6.2.1. Canada Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
12.6.2.1.1. 99%
12.6.2.1.2. 97%
12.6.2.1.3. 95%
12.6.2.1.4. Others
12.6.2.2. Canada Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
12.6.2.2.1. Therapeutic
12.6.2.2.1.1. Respiratory
Tract Infections
12.6.2.2.1.2. Skin
And Skin Structure Infections
12.6.2.2.1.3. Urinary
Tract Infections
12.6.2.2.1.4. Intra-Abdominal
Infections
12.6.2.2.1.5. Community-acquired
Pneumonia
12.6.2.2.1.6. Others
12.6.2.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
12.6.2.2.3. Plant Biology
12.6.2.2.4. Others
12.6.2.3. Canada Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.2.3.1. Research Institutions
12.6.2.3.2. Pharmaceutical and Drug Manufacturing Companies
12.6.2.3.3. Others
12.6.2.4. Canada Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
12.6.2.4.1. Online
12.6.2.4.2. Offline
12.6.3. Mexico
12.6.3.1. Mexico Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
12.6.3.1.1. 99%
12.6.3.1.2. 97%
12.6.3.1.3. 95%
12.6.3.1.4. Others
12.6.3.2. Mexico Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
12.6.3.2.1. Therapeutic
12.6.3.2.1.1. Respiratory
Tract Infections
12.6.3.2.1.2. Skin
And Skin Structure Infections
12.6.3.2.1.3. Urinary
Tract Infections
12.6.3.2.1.4. Intra-Abdominal
Infections
12.6.3.2.1.5. Community-acquired
Pneumonia
12.6.3.2.1.6. Others
12.6.3.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
12.6.3.2.3. Plant Biology
12.6.3.2.4. Others
12.6.3.3. Mexico Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
12.6.3.3.1. Research Institutions
12.6.3.3.2. Pharmaceutical and Drug Manufacturing Companies
12.6.3.3.3. Others
12.6.3.4. Mexico Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
12.6.3.4.1. Online
12.6.3.4.2. Offline
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Piperacillin Acid (CAS 61477-96-1)
Market Revenue (US$ Mn) and Forecasts, By Purity
12.6.4.1.1. 99%
12.6.4.1.2. 97%
12.6.4.1.3. 95%
12.6.4.1.4. Others
12.6.4.2. Rest of North America Piperacillin Acid (CAS 61477-96-1)
Market Revenue (US$ Mn) and Forecasts, By Application
12.6.4.2.1. Therapeutic
12.6.4.2.1.1. Respiratory
Tract Infections
12.6.4.2.1.2. Skin
And Skin Structure Infections
12.6.4.2.1.3. Urinary
Tract Infections
12.6.4.2.1.4. Intra-Abdominal
Infections
12.6.4.2.1.5. Community-acquired
Pneumonia
12.6.4.2.1.6. Others
12.6.4.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
12.6.4.2.3. Plant Biology
12.6.4.2.4. Others
12.6.4.3. Rest of North America Piperacillin Acid (CAS 61477-96-1)
Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.3.1. Research Institutions
12.6.4.3.2. Pharmaceutical and Drug Manufacturing Companies
12.6.4.3.3. Others
12.6.4.4. Rest of North America Piperacillin Acid (CAS 61477-96-1)
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.6.4.4.1. Online
12.6.4.4.2. Offline
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Purity
12.7.3. By
Application
12.7.4. By End
Users
12.7.5. By
Distribution Channel
13. Europe Piperacillin Acid (CAS 61477-96-1) Market Analysis and
Forecasts, 2020 - 2028
13.1. Overview
13.1.1. Europe
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
13.2. Europe
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts, By Purity
13.2.1. 99%
13.2.2. 97%
13.2.3. 95%
13.2.4. Others
13.3. Europe
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts, By
Application
13.3.1. Therapeutic
13.3.1.1. Respiratory Tract Infections
13.3.1.2. Skin And Skin Structure Infections
13.3.1.3. Urinary Tract Infections
13.3.1.4. Intra-Abdominal Infections
13.3.1.5. Community-acquired Pneumonia
13.3.1.6. Others
13.3.2. Clinical
In-Vitro Microbiological Antimicrobial Susceptibility Tests (Panels, Discs, and
MIC Strips)
13.3.3. Plant
Biology
13.3.4. Others
13.4. Europe
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts, By
End Users
13.4.1. Research
Institutions
13.4.2. Pharmaceutical
and Drug Manufacturing Companies
13.4.3. Others
13.5. Europe
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.5.1. Online
13.5.2. Offline
13.6. Europe
Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.1. France
13.6.1.1. France Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
13.6.1.1.1. 99%
13.6.1.1.2. 97%
13.6.1.1.3. 95%
13.6.1.1.4. Others
13.6.1.2. France Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
13.6.1.2.1. Therapeutic
13.6.1.2.1.1. Respiratory
Tract Infections
13.6.1.2.1.2. Skin
And Skin Structure Infections
13.6.1.2.1.3. Urinary
Tract Infections
13.6.1.2.1.4. Intra-Abdominal
Infections
13.6.1.2.1.5. Community-acquired
Pneumonia
13.6.1.2.1.6. Others
13.6.1.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
13.6.1.2.3. Plant Biology
13.6.1.2.4. Others
13.6.1.3. France Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.1.3.1. Research Institutions
13.6.1.3.2. Pharmaceutical and Drug Manufacturing Companies
13.6.1.3.3. Others
13.6.1.4. France Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.1.4.1. Online
13.6.1.4.2. Offline
13.6.2. The UK
13.6.2.1. The UK Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
13.6.2.1.1. 99%
13.6.2.1.2. 97%
13.6.2.1.3. 95%
13.6.2.1.4. Others
13.6.2.2. The UK Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
13.6.2.2.1. Therapeutic
13.6.2.2.1.1. Respiratory
Tract Infections
13.6.2.2.1.2. Skin
And Skin Structure Infections
13.6.2.2.1.3. Urinary
Tract Infections
13.6.2.2.1.4. Intra-Abdominal
Infections
13.6.2.2.1.5. Community-acquired
Pneumonia
13.6.2.2.1.6. Others
13.6.2.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
13.6.2.2.3. Plant Biology
13.6.2.2.4. Others
13.6.2.3. The UK Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.2.3.1. Research Institutions
13.6.2.3.2. Pharmaceutical and Drug Manufacturing Companies
13.6.2.3.3. Others
13.6.2.4. The UK Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.2.4.1. Online
13.6.2.4.2. Offline
13.6.3. Spain
13.6.3.1. Spain Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
13.6.3.1.1. 99%
13.6.3.1.2. 97%
13.6.3.1.3. 95%
13.6.3.1.4. Others
13.6.3.2. Spain Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.3.2.1. Therapeutic
13.6.3.2.1.1. Respiratory
Tract Infections
13.6.3.2.1.2. Skin
And Skin Structure Infections
13.6.3.2.1.3. Urinary
Tract Infections
13.6.3.2.1.4. Intra-Abdominal
Infections
13.6.3.2.1.5. Community-acquired
Pneumonia
13.6.3.2.1.6. Others
13.6.3.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
13.6.3.2.3. Plant Biology
13.6.3.2.4. Others
13.6.3.3. Spain Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.3.3.1. Research Institutions
13.6.3.3.2. Pharmaceutical and Drug Manufacturing Companies
13.6.3.3.3. Others
13.6.3.4. Spain Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.3.4.1. Online
13.6.3.4.2. Offline
13.6.4. Germany
13.6.4.1. Germany Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
13.6.4.1.1. 99%
13.6.4.1.2. 97%
13.6.4.1.3. 95%
13.6.4.1.4. Others
13.6.4.2. Germany Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
13.6.4.2.1. Therapeutic
13.6.4.2.1.1. Respiratory
Tract Infections
13.6.4.2.1.2. Skin
And Skin Structure Infections
13.6.4.2.1.3. Urinary
Tract Infections
13.6.4.2.1.4. Intra-Abdominal
Infections
13.6.4.2.1.5. Community-acquired
Pneumonia
13.6.4.2.1.6. Others
13.6.4.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
13.6.4.2.3. Plant Biology
13.6.4.2.4. Others
13.6.4.3. Germany Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.4.3.1. Research Institutions
13.6.4.3.2. Pharmaceutical and Drug Manufacturing Companies
13.6.4.3.3. Others
13.6.4.4. Germany Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.4.4.1. Online
13.6.4.4.2. Offline
13.6.5. Italy
13.6.5.1. Italy Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
13.6.5.1.1. 99%
13.6.5.1.2. 97%
13.6.5.1.3. 95%
13.6.5.1.4. Others
13.6.5.2. Italy Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
13.6.5.2.1. Therapeutic
13.6.5.2.1.1. Respiratory
Tract Infections
13.6.5.2.1.2. Skin
And Skin Structure Infections
13.6.5.2.1.3. Urinary
Tract Infections
13.6.5.2.1.4. Intra-Abdominal
Infections
13.6.5.2.1.5. Community-acquired
Pneumonia
13.6.5.2.1.6. Others
13.6.5.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
13.6.5.2.3. Plant Biology
13.6.5.2.4. Others
13.6.5.3. Italy Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.5.3.1. Research Institutions
13.6.5.3.2. Pharmaceutical and Drug Manufacturing Companies
13.6.5.3.3. Others
13.6.5.4. Italy Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.5.4.1. Online
13.6.5.4.2. Offline
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Purity
13.6.6.1.1. 99%
13.6.6.1.2. 97%
13.6.6.1.3. 95%
13.6.6.1.4. Others
13.6.6.2. Nordic Countries Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Application
13.6.6.2.1. Therapeutic
13.6.6.2.1.1. Respiratory
Tract Infections
13.6.6.2.1.2. Skin
And Skin Structure Infections
13.6.6.2.1.3. Urinary
Tract Infections
13.6.6.2.1.4. Intra-Abdominal
Infections
13.6.6.2.1.5. Community-acquired
Pneumonia
13.6.6.2.1.6. Others
13.6.6.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
13.6.6.2.3. Plant Biology
13.6.6.2.4. Others
13.6.6.3. Nordic Countries Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.3.1. Research Institutions
13.6.6.3.2. Pharmaceutical and Drug Manufacturing Companies
13.6.6.3.3. Others
13.6.6.4. Nordic Countries Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.6.4.1. Online
13.6.6.4.2. Offline
13.6.6.5. Nordic Countries Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Purity
13.6.7.1.1. 99%
13.6.7.1.2. 97%
13.6.7.1.3. 95%
13.6.7.1.4. Others
13.6.7.2. Benelux Union Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Application
13.6.7.2.1. Therapeutic
13.6.7.2.1.1. Respiratory
Tract Infections
13.6.7.2.1.2. Skin
And Skin Structure Infections
13.6.7.2.1.3. Urinary
Tract Infections
13.6.7.2.1.4. Intra-Abdominal
Infections
13.6.7.2.1.5. Community-acquired
Pneumonia
13.6.7.2.1.6. Others
13.6.7.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
13.6.7.2.3. Plant Biology
13.6.7.2.4. Others
13.6.7.3. Benelux Union Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.7.3.1. Research Institutions
13.6.7.3.2. Pharmaceutical and Drug Manufacturing Companies
13.6.7.3.3. Others
13.6.7.4. Benelux Union Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.7.4.1. Online
13.6.7.4.2. Offline
13.6.7.5. Benelux Union Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Purity
13.6.8.1.1. 99%
13.6.8.1.2. 97%
13.6.8.1.3. 95%
13.6.8.1.4. Others
13.6.8.2. Rest of Europe Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.8.2.1. Therapeutic
13.6.8.2.1.1. Respiratory
Tract Infections
13.6.8.2.1.2. Skin
And Skin Structure Infections
13.6.8.2.1.3. Urinary
Tract Infections
13.6.8.2.1.4. Intra-Abdominal
Infections
13.6.8.2.1.5. Community-acquired
Pneumonia
13.6.8.2.1.6. Others
13.6.8.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
13.6.8.2.3. Plant Biology
13.6.8.2.4. Others
13.6.8.3. Rest of Europe Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By End Users
13.6.8.3.1. Research Institutions
13.6.8.3.2. Pharmaceutical and Drug Manufacturing Companies
13.6.8.3.3. Others
13.6.8.4. Rest of Europe Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.6.8.4.1. Online
13.6.8.4.2. Offline
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Purity
13.7.3. By
Application
13.7.4. By End
Users
13.7.5. By
Distribution Channel
14. Asia Pacific Piperacillin Acid (CAS 61477-96-1) Market
Analysis and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Asia
Pacific Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
14.2. Asia
Pacific Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts,
By Purity
14.2.1. 99%
14.2.2. 97%
14.2.3. 95%
14.2.4. Others
14.3. Asia
Pacific Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Application
14.3.1. Therapeutic
14.3.1.1. Respiratory Tract Infections
14.3.1.2. Skin And Skin Structure Infections
14.3.1.3. Urinary Tract Infections
14.3.1.4. Intra-Abdominal Infections
14.3.1.5. Community-acquired Pneumonia
14.3.1.6. Others
14.3.2. Clinical
In-Vitro Microbiological Antimicrobial Susceptibility Tests (Panels, Discs, and
MIC Strips)
14.3.3. Plant
Biology
14.3.4. Others
14.4. Asia
Pacific Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By End Users
14.4.1. Research
Institutions
14.4.2. Pharmaceutical
and Drug Manufacturing Companies
14.4.3. Others
14.5. Asia
Pacific Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.5.1. Online
14.5.2. Offline
14.6. Asia
Pacific Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Country
14.6.1. China
14.6.1.1. China Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
14.6.1.1.1. 99%
14.6.1.1.2. 97%
14.6.1.1.3. 95%
14.6.1.1.4. Others
14.6.1.2. China Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
14.6.1.2.1. Therapeutic
14.6.1.2.1.1. Respiratory
Tract Infections
14.6.1.2.1.2. Skin
And Skin Structure Infections
14.6.1.2.1.3. Urinary
Tract Infections
14.6.1.2.1.4. Intra-Abdominal
Infections
14.6.1.2.1.5. Community-acquired
Pneumonia
14.6.1.2.1.6. Others
14.6.1.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
14.6.1.2.3. Plant Biology
14.6.1.2.4. Others
14.6.1.3. China Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.1.3.1. Research Institutions
14.6.1.3.2. Pharmaceutical and Drug Manufacturing Companies
14.6.1.3.3. Others
14.6.1.4. China Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
14.6.1.4.1. Online
14.6.1.4.2. Offline
14.6.2. Japan
14.6.2.1. Japan Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
14.6.2.1.1. 99%
14.6.2.1.2. 97%
14.6.2.1.3. 95%
14.6.2.1.4. Others
14.6.2.2. Japan Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
14.6.2.2.1. Therapeutic
14.6.2.2.1.1. Respiratory
Tract Infections
14.6.2.2.1.2. Skin
And Skin Structure Infections
14.6.2.2.1.3. Urinary
Tract Infections
14.6.2.2.1.4. Intra-Abdominal
Infections
14.6.2.2.1.5. Community-acquired
Pneumonia
14.6.2.2.1.6. Others
14.6.2.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
14.6.2.2.3. Plant Biology
14.6.2.2.4. Others
14.6.2.3. Japan Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.2.3.1. Research Institutions
14.6.2.3.2. Pharmaceutical and Drug Manufacturing Companies
14.6.2.3.3. Others
14.6.2.4. Japan Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
14.6.2.4.1. Online
14.6.2.4.2. Offline
14.6.3. India
14.6.3.1. India Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
14.6.3.1.1. 99%
14.6.3.1.2. 97%
14.6.3.1.3. 95%
14.6.3.1.4. Others
14.6.3.2. India Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
14.6.3.2.1. Therapeutic
14.6.3.2.1.1. Respiratory
Tract Infections
14.6.3.2.1.2. Skin
And Skin Structure Infections
14.6.3.2.1.3. Urinary
Tract Infections
14.6.3.2.1.4. Intra-Abdominal
Infections
14.6.3.2.1.5. Community-acquired
Pneumonia
14.6.3.2.1.6. Others
14.6.3.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
14.6.3.2.3. Plant Biology
14.6.3.2.4. Others
14.6.3.3. India Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
14.6.3.3.1. Research Institutions
14.6.3.3.2. Pharmaceutical and Drug Manufacturing Companies
14.6.3.3.3. Others
14.6.3.4. India Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
14.6.3.4.1. Online
14.6.3.4.2. Offline
14.6.4. New
Zealand
14.6.4.1. New Zealand Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Purity
14.6.4.1.1. 99%
14.6.4.1.2. 97%
14.6.4.1.3. 95%
14.6.4.1.4. Others
14.6.4.2. New Zealand Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.4.2.1. Therapeutic
14.6.4.2.1.1. Respiratory
Tract Infections
14.6.4.2.1.2. Skin
And Skin Structure Infections
14.6.4.2.1.3. Urinary
Tract Infections
14.6.4.2.1.4. Intra-Abdominal
Infections
14.6.4.2.1.5. Community-acquired
Pneumonia
14.6.4.2.1.6. Others
14.6.4.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
14.6.4.2.3. Plant Biology
14.6.4.2.4. Others
14.6.4.3. New Zealand Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.4.3.1. Research Institutions
14.6.4.3.2. Pharmaceutical and Drug Manufacturing Companies
14.6.4.3.3. Others
14.6.4.4. New Zealand Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
14.6.4.4.1. Online
14.6.4.4.2. Offline
14.6.5. Australia
14.6.5.1. Australia Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Purity
14.6.5.1.1. 99%
14.6.5.1.2. 97%
14.6.5.1.3. 95%
14.6.5.1.4. Others
14.6.5.2. Australia Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.5.2.1. Therapeutic
14.6.5.2.1.1. Respiratory
Tract Infections
14.6.5.2.1.2. Skin
And Skin Structure Infections
14.6.5.2.1.3. Urinary
Tract Infections
14.6.5.2.1.4. Intra-Abdominal
Infections
14.6.5.2.1.5. Community-acquired
Pneumonia
14.6.5.2.1.6. Others
14.6.5.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
14.6.5.2.3. Plant Biology
14.6.5.2.4. Others
14.6.5.3. Australia Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.5.3.1. Research Institutions
14.6.5.3.2. Pharmaceutical and Drug Manufacturing Companies
14.6.5.3.3. Others
14.6.5.4. Australia Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
14.6.5.4.1. Online
14.6.5.4.2. Offline
14.6.6. South
Korea
14.6.6.1. South Korea Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Purity
14.6.6.1.1. 99%
14.6.6.1.2. 97%
14.6.6.1.3. 95%
14.6.6.1.4. Others
14.6.6.2. South Korea Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.6.2.1. Therapeutic
14.6.6.2.1.1. Respiratory
Tract Infections
14.6.6.2.1.2. Skin
And Skin Structure Infections
14.6.6.2.1.3. Urinary
Tract Infections
14.6.6.2.1.4. Intra-Abdominal
Infections
14.6.6.2.1.5. Community-acquired
Pneumonia
14.6.6.2.1.6. Others
14.6.6.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
14.6.6.2.3. Plant Biology
14.6.6.2.4. Others
14.6.6.3. South Korea Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.6.3.1. Research Institutions
14.6.6.3.2. Pharmaceutical and Drug Manufacturing Companies
14.6.6.3.3. Others
14.6.6.4. South Korea Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
14.6.6.4.1. Online
14.6.6.4.2. Offline
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Purity
14.6.7.1.1. 99%
14.6.7.1.2. 97%
14.6.7.1.3. 95%
14.6.7.1.4. Others
14.6.7.2. Southeast Asia Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.7.2.1. Therapeutic
14.6.7.2.1.1. Respiratory
Tract Infections
14.6.7.2.1.2. Skin
And Skin Structure Infections
14.6.7.2.1.3. Urinary
Tract Infections
14.6.7.2.1.4. Intra-Abdominal
Infections
14.6.7.2.1.5. Community-acquired
Pneumonia
14.6.7.2.1.6. Others
14.6.7.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
14.6.7.2.3. Plant Biology
14.6.7.2.4. Others
14.6.7.3. Southeast Asia Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.7.3.1. Research Institutions
14.6.7.3.2. Pharmaceutical and Drug Manufacturing Companies
14.6.7.3.3. Others
14.6.7.4. Southeast Asia Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.7.4.1. Online
14.6.7.4.2. Offline
14.6.7.5. Southeast Asia Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Purity
14.6.8.1.1. 99%
14.6.8.1.2. 97%
14.6.8.1.3. 95%
14.6.8.1.4. Others
14.6.8.2. Rest of Asia Pacific Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Application
14.6.8.2.1. Therapeutic
14.6.8.2.1.1. Respiratory
Tract Infections
14.6.8.2.1.2. Skin
And Skin Structure Infections
14.6.8.2.1.3. Urinary
Tract Infections
14.6.8.2.1.4. Intra-Abdominal
Infections
14.6.8.2.1.5. Community-acquired
Pneumonia
14.6.8.2.1.6. Others
14.6.8.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
14.6.8.2.3. Plant Biology
14.6.8.2.4. Others
14.6.8.3. Rest of Asia Pacific Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.3.1. Research Institutions
14.6.8.3.2. Pharmaceutical and Drug Manufacturing Companies
14.6.8.3.3. Others
14.6.8.4. Rest of Asia Pacific Piperacillin Acid (CAS 61477-96-1) Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.6.8.4.1. Online
14.6.8.4.2. Offline
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Purity
14.7.3. By
Application
14.7.4. By End
Users
14.7.5. By
Distribution Channel
15. Middle East and Africa Piperacillin Acid (CAS 61477-96-1)
Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Middle
East and Africa Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
15.2. Middle
East and Africa Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Purity
15.2.1. 99%
15.2.2. 97%
15.2.3. 95%
15.2.4. Others
15.3. Middle
East and Africa Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Application
15.3.1. Therapeutic
15.3.1.1. Respiratory Tract Infections
15.3.1.2. Skin And Skin Structure Infections
15.3.1.3. Urinary Tract Infections
15.3.1.4. Intra-Abdominal Infections
15.3.1.5. Community-acquired Pneumonia
15.3.1.6. Others
15.3.2. Clinical
In-Vitro Microbiological Antimicrobial Susceptibility Tests (Panels, Discs, and
MIC Strips)
15.3.3. Plant
Biology
15.3.4. Others
15.4. Middle
East and Africa Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By End Users
15.4.1. Research
Institutions
15.4.2. Pharmaceutical
and Drug Manufacturing Companies
15.4.3. Others
15.5. Middle
East and Africa Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.5.1. Online
15.5.2. Offline
15.6. Middle
East and Africa Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Purity
15.6.1.1.1. 99%
15.6.1.1.2. 97%
15.6.1.1.3. 95%
15.6.1.1.4. Others
15.6.1.2. Saudi Arabia Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.1.2.1. Therapeutic
15.6.1.2.1.1. Respiratory
Tract Infections
15.6.1.2.1.2. Skin
And Skin Structure Infections
15.6.1.2.1.3. Urinary
Tract Infections
15.6.1.2.1.4. Intra-Abdominal
Infections
15.6.1.2.1.5. Community-acquired
Pneumonia
15.6.1.2.1.6. Others
15.6.1.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
15.6.1.2.3. Plant Biology
15.6.1.2.4. Others
15.6.1.3. Saudi Arabia Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By End Users
15.6.1.3.1. Research Institutions
15.6.1.3.2. Pharmaceutical and Drug Manufacturing Companies
15.6.1.3.3. Others
15.6.1.4. Saudi Arabia Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
15.6.1.4.1. Online
15.6.1.4.2. Offline
15.6.2. UAE
15.6.2.1. UAE Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
and Forecasts, By Purity
15.6.2.1.1. 99%
15.6.2.1.2. 97%
15.6.2.1.3. 95%
15.6.2.1.4. Others
15.6.2.2. UAE Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.2.2.1. Therapeutic
15.6.2.2.1.1. Respiratory
Tract Infections
15.6.2.2.1.2. Skin
And Skin Structure Infections
15.6.2.2.1.3. Urinary
Tract Infections
15.6.2.2.1.4. Intra-Abdominal
Infections
15.6.2.2.1.5. Community-acquired
Pneumonia
15.6.2.2.1.6. Others
15.6.2.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
15.6.2.2.3. Plant Biology
15.6.2.2.4. Others
15.6.2.3. UAE Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
and Forecasts, By End Users
15.6.2.3.1. Research Institutions
15.6.2.3.2. Pharmaceutical and Drug Manufacturing Companies
15.6.2.3.3. Others
15.6.2.4. UAE Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
15.6.2.4.1. Online
15.6.2.4.2. Offline
15.6.3. Egypt
15.6.3.1. Egypt Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
15.6.3.1.1. 99%
15.6.3.1.2. 97%
15.6.3.1.3. 95%
15.6.3.1.4. Others
15.6.3.2. Egypt Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
15.6.3.2.1. Therapeutic
15.6.3.2.1.1. Respiratory
Tract Infections
15.6.3.2.1.2. Skin
And Skin Structure Infections
15.6.3.2.1.3. Urinary
Tract Infections
15.6.3.2.1.4. Intra-Abdominal
Infections
15.6.3.2.1.5. Community-acquired
Pneumonia
15.6.3.2.1.6. Others
15.6.3.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
15.6.3.2.3. Plant Biology
15.6.3.2.4. Others
15.6.3.3. Egypt Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
15.6.3.3.1. Research Institutions
15.6.3.3.2. Pharmaceutical and Drug Manufacturing Companies
15.6.3.3.3. Others
15.6.3.4. Egypt Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
15.6.3.4.1. Online
15.6.3.4.2. Offline
15.6.4. Kuwait
15.6.4.1. Kuwait Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
15.6.4.1.1. 99%
15.6.4.1.2. 97%
15.6.4.1.3. 95%
15.6.4.1.4. Others
15.6.4.2. Kuwait Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
15.6.4.2.1. Therapeutic
15.6.4.2.1.1. Respiratory
Tract Infections
15.6.4.2.1.2. Skin
And Skin Structure Infections
15.6.4.2.1.3. Urinary
Tract Infections
15.6.4.2.1.4. Intra-Abdominal
Infections
15.6.4.2.1.5. Community-acquired
Pneumonia
15.6.4.2.1.6. Others
15.6.4.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
15.6.4.2.3. Plant Biology
15.6.4.2.4. Others
15.6.4.3. Kuwait Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
15.6.4.3.1. Research Institutions
15.6.4.3.2. Pharmaceutical and Drug Manufacturing Companies
15.6.4.3.3. Others
15.6.4.4. Kuwait Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
15.6.4.4.1. Online
15.6.4.4.2. Offline
15.6.5. South
Africa
15.6.5.1. South Africa Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Purity
15.6.5.1.1. 99%
15.6.5.1.2. 97%
15.6.5.1.3. 95%
15.6.5.1.4. Others
15.6.5.2. South Africa Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Application
15.6.5.2.1. Therapeutic
15.6.5.2.1.1. Respiratory
Tract Infections
15.6.5.2.1.2. Skin
And Skin Structure Infections
15.6.5.2.1.3. Urinary
Tract Infections
15.6.5.2.1.4. Intra-Abdominal
Infections
15.6.5.2.1.5. Community-acquired
Pneumonia
15.6.5.2.1.6. Others
15.6.5.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
15.6.5.2.3. Plant Biology
15.6.5.2.4. Others
15.6.5.3. South Africa Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By End Users
15.6.5.3.1. Research Institutions
15.6.5.3.2. Pharmaceutical and Drug Manufacturing Companies
15.6.5.3.3. Others
15.6.5.4. South Africa Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
15.6.5.4.1. Online
15.6.5.4.2. Offline
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Piperacillin Acid (CAS
61477-96-1) Market Revenue (US$ Mn) and Forecasts, By Purity
15.6.6.1.1. 99%
15.6.6.1.2. 97%
15.6.6.1.3. 95%
15.6.6.1.4. Others
15.6.6.2. Rest of Middle East & Africa Piperacillin Acid (CAS
61477-96-1) Market Revenue (US$ Mn) and Forecasts, By Application
15.6.6.2.1. Therapeutic
15.6.6.2.1.1. Respiratory
Tract Infections
15.6.6.2.1.2. Skin
And Skin Structure Infections
15.6.6.2.1.3. Urinary
Tract Infections
15.6.6.2.1.4. Intra-Abdominal
Infections
15.6.6.2.1.5. Community-acquired
Pneumonia
15.6.6.2.1.6. Others
15.6.6.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
15.6.6.2.3. Plant Biology
15.6.6.2.4. Others
15.6.6.3. Rest of Middle East & Africa Piperacillin Acid (CAS
61477-96-1) Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.3.1. Research Institutions
15.6.6.3.2. Pharmaceutical and Drug Manufacturing Companies
15.6.6.3.3. Others
15.6.6.4. Rest of Middle East & Africa Piperacillin Acid (CAS
61477-96-1) Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.6.4.1. Online
15.6.6.4.2. Offline
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Purity
15.7.3. By
Application
15.7.4. By End
Users
15.7.5. By
Distribution Channel
16. Latin America Piperacillin Acid (CAS 61477-96-1) Market
Analysis and Forecasts, 2020 - 2028
16.1. Overview
16.1.1. Latin
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn)
16.2. Latin
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Purity
16.2.1. 99%
16.2.2. 97%
16.2.3. 95%
16.2.4. Others
16.3. Latin
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Application
16.3.1. Therapeutic
16.3.1.1. Respiratory Tract Infections
16.3.1.2. Skin And Skin Structure Infections
16.3.1.3. Urinary Tract Infections
16.3.1.4. Intra-Abdominal Infections
16.3.1.5. Community-acquired Pneumonia
16.3.1.6. Others
16.3.2. Clinical
In-Vitro Microbiological Antimicrobial Susceptibility Tests (Panels, Discs, and
MIC Strips)
16.3.3. Plant
Biology
16.3.4. Others
16.4. Latin
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By End Users
16.4.1. Research
Institutions
16.4.2. Pharmaceutical
and Drug Manufacturing Companies
16.4.3. Others
16.5. Latin
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
16.5.1. Online
16.5.2. Offline
16.6. Latin
America Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$ Mn) and
Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Purity
16.6.1.1.1. 99%
16.6.1.1.2. 97%
16.6.1.1.3. 95%
16.6.1.1.4. Others
16.6.1.2. Brazil Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Application
16.6.1.2.1. Therapeutic
16.6.1.2.1.1. Respiratory
Tract Infections
16.6.1.2.1.2. Skin
And Skin Structure Infections
16.6.1.2.1.3. Urinary
Tract Infections
16.6.1.2.1.4. Intra-Abdominal
Infections
16.6.1.2.1.5. Community-acquired
Pneumonia
16.6.1.2.1.6. Others
16.6.1.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
16.6.1.2.3. Plant Biology
16.6.1.2.4. Others
16.6.1.3. Brazil Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By End Users
16.6.1.3.1. Research Institutions
16.6.1.3.2. Pharmaceutical and Drug Manufacturing Companies
16.6.1.3.3. Others
16.6.1.4. Brazil Piperacillin Acid (CAS 61477-96-1) Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
16.6.1.4.1. Online
16.6.1.4.2. Offline
16.6.2. Argentina
16.6.2.1. Argentina Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Purity
16.6.2.1.1. 99%
16.6.2.1.2. 97%
16.6.2.1.3. 95%
16.6.2.1.4. Others
16.6.2.2. Argentina Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Application
16.6.2.2.1. Therapeutic
16.6.2.2.1.1. Respiratory
Tract Infections
16.6.2.2.1.2. Skin
And Skin Structure Infections
16.6.2.2.1.3. Urinary
Tract Infections
16.6.2.2.1.4. Intra-Abdominal
Infections
16.6.2.2.1.5. Community-acquired
Pneumonia
16.6.2.2.1.6. Others
16.6.2.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
16.6.2.2.3. Plant Biology
16.6.2.2.4. Others
16.6.2.3. Argentina Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By End Users
16.6.2.3.1. Research Institutions
16.6.2.3.2. Pharmaceutical and Drug Manufacturing Companies
16.6.2.3.3. Others
16.6.2.4. Argentina Piperacillin Acid (CAS 61477-96-1) Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
16.6.2.4.1. Online
16.6.2.4.2. Offline
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Piperacillin Acid (CAS 61477-96-1)
Market Revenue (US$ Mn) and Forecasts, By Purity
16.6.3.1.1. 99%
16.6.3.1.2. 97%
16.6.3.1.3. 95%
16.6.3.1.4. Others
16.6.3.2. Rest of Latin America Piperacillin Acid (CAS 61477-96-1)
Market Revenue (US$ Mn) and Forecasts, By Application
16.6.3.2.1. Therapeutic
16.6.3.2.1.1. Respiratory
Tract Infections
16.6.3.2.1.2. Skin
And Skin Structure Infections
16.6.3.2.1.3. Urinary
Tract Infections
16.6.3.2.1.4. Intra-Abdominal
Infections
16.6.3.2.1.5. Community-acquired
Pneumonia
16.6.3.2.1.6. Others
16.6.3.2.2. Clinical In-Vitro Microbiological Antimicrobial Susceptibility
Tests (Panels, Discs, and MIC Strips)
16.6.3.2.3. Plant Biology
16.6.3.2.4. Others
16.6.3.3. Rest of Latin America Piperacillin Acid (CAS 61477-96-1)
Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.3.3.1. Research Institutions
16.6.3.3.2. Pharmaceutical and Drug Manufacturing Companies
16.6.3.3.3. Others
16.6.3.4. Rest of Latin America Piperacillin Acid (CAS 61477-96-1)
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
16.6.3.4.1. Online
16.6.3.4.2. Offline
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Purity
16.7.3. By
Application
16.7.4. By End
Users
16.7.5. By
Distribution Channel
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2019
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. AK
Scientific Inc.
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. ALB Technology
Limited.
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business Strategies
18.3. BOC Sciences
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Glentham Life Sciences Limited
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. GoldBio
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. hairuichem.com
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Jiangxi Fushine Pharmaceutical
Co., Ltd.
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Jigs chemical
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. LGC Limited
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. LKT Laboratories
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. mos-chemical.com (MOSINTER
GROUP LIMITED)
18.11.1.
Company Details
18.11.2.
Company Overview
18.11.3.
Product Offerings
18.11.4.
Key Developments
18.11.5.
Financial Analysis
18.11.6.
SWOT Analysis
18.11.7. Business
Strategies
18.12. MuseChem
18.12.1.
Company Details
18.12.2.
Company Overview
18.12.3.
Product Offerings
18.12.4.
Key Developments
18.12.5.
Financial Analysis
18.12.6.
SWOT Analysis
18.12.7. Business
Strategies
18.13. Targetmol
18.13.1.
Company Details
18.13.2.
Company Overview
18.13.3.
Product Offerings
18.13.4.
Key Developments
18.13.5.
Financial Analysis
18.13.6.
SWOT Analysis
18.13.7. Business
Strategies
18.14. Thermo Fisher Scientific (Alfa
Aesar)
18.14.1.
Company Details
18.14.2.
Company Overview
18.14.3.
Product Offerings
18.14.4.
Key Developments
18.14.5.
Financial Analysis
18.14.6.
SWOT Analysis
18.14.7. Business
Strategies
18.15. TOKU-E
18.15.1.
Company Details
18.15.2.
Company Overview
18.15.3.
Product Offerings
18.15.4.
Key Developments
18.15.5.
Financial Analysis
18.15.6.
SWOT Analysis
18.15.7. Business
Strategies
18.16. United States Biological
18.16.1.
Company Details
18.16.2.
Company Overview
18.16.3.
Product Offerings
18.16.4.
Key Developments
18.16.5.
Financial Analysis
18.16.6.
SWOT Analysis
18.16.7. Business Strategies
18.17. Other
Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
![AMI AMI](https://www.absolutemarketsinsights.com/upload/Research_Scope2.jpg)
![AMI AMI](https://www.absolutemarketsinsights.com/upload/Global_IMG2.jpg)
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.
![AMI AMI](https://www.absolutemarketsinsights.com/images/iso_form.jpg)